Drug Trial Radar · NCT07158242
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 15, 2026
Primary completion
Mar 31, 2030
Study completion Mar 31, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).
Conditions
- Moderately to Severely Active Ulcerative Colitis
Interventions
AfimkibartDrug
Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinical Remission at Week 52Time frame: At Week 52
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Connecticut Children's Medical Center
Hartford, Connecticut · Recruiting
University of South Florida
Tampa, Florida · Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
Washington University
St Louis, Missouri · Recruiting
Northwell Health
Lake Success, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
Cleveland Clinic;Children's Institute
Cleveland, Ohio · Recruiting
UPMC Childen?s Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Texas Digestive Specialists
Harlingen, Texas · Recruiting
Mater Hospital Brisbane
South Brisbane, Queensland, Australia · Recruiting
Royal Childrens Hospital
Parkville, Victoria, Australia · Recruiting
Perth Children's Hospital
Nedlands, Western Australia, Australia · Recruiting
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
CECIP - Centro de Estudos Clínicos do Interior Paulista
Jaú, São Paulo, Brazil · Recruiting
BR Trials - Pesquisa Clínica
São Paulo, São Paulo, Brazil · Recruiting
Hospital For Sick Children
Toronto, Ontario, Canada · Recruiting
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China · Recruiting
Children's Hospital ZheJiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
IATROS International
Bloemfontein, South Africa · Recruiting
Emmed Research
Pretoria, South Africa · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Chulalongkorn University
Bangkok, Thailand · Recruiting
Siriraj Hospital
Bangkok, Thailand · Recruiting
Ramathibodi Hospital
Bangkok, Thailand · Recruiting
Birmingham Children's Hospital
Birmingham, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, United Kingdom · Recruiting
Great North Children's Hospital
Newcastle upon Tyne, United Kingdom · Recruiting
Sheffield Childrens Hospital
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.